Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
-
Future-Driven Intelligent R&D–AI for Life Sciences and Drug Discovery
-
The Era of Superintelligent Agents for Chinese Innovative Drugs
-
Panel Discussion: AI-Empowered Four-in-One Translation Platform
-
AI-Driven Innovation Practices in Pharmaceutical Enterprises
-
AI·Intelligent Transformation: From Data Foundation to Scenario Value
-
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
U.S. Biotech Tensions and the Future Road for Chinese Pharmaceutical Companies Going Global Session
-
July 22, 14:00–17:30
The Booming Radiopharmaceuticals Session
Stay tuned
planner
Tao Xu:Founder & CEO, SmartNuclide; Secretary-General, Tonacea Radiopharmaceutical Club
Hong Liu:Head of the Scientific Research Project Management Department (Postdoctoral Workstation) of Guangzhou Pharmaceutical Holdings Limited, Board Director of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, Chairman and General Manager of Guangzhou Baiyunshan XIHE Health Pharmaceutical Co., Ltd
14:00-14:05 Moderator
Yumin Zhang :Founder, Anchoray Inc; Radiopharmaceutical Advisor, Tonacea; Honorary Chairman, Chinese American Society of Nuclear Medicine and Molecular Imaging (CASNMMI)
14:05-14:10 Opening Remarks
Hong Liu:Head of the Scientific Research Project Management Department (Postdoctoral Workstation) of Guangzhou Pharmaceutical Holdings Limited, Board Director of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, Chairman and General Manager of Guangzhou Baiyunshan XIHE Health Pharmaceutical Co., Ltd
14:10-14:30 Innovative Design of Radiopharmaceuticals
Zhen Cheng:Director, Molecular Imaging Center, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences; Fellow of American Institute for Medical and Biological Engineering, Society of Radiopharmaceutical Sciences, International Society for Optics and Photonics, Royal Society of Chemistry, and International Association of Advanced Materials
14:30-14:45 Clinical Development Strategies of Radiotherapeutic Drugs in Tumor Therapy
Gloria Gong:CEO, Foresight Pharma Consulting; Advisor for Bain & Company
14:54-15:00 Integrating RDC and ADC Theranostics for Improving Oncology Standard of Care
Zhican Qu:Chairman and CSO, Nanolattix Biotech
15:00-15:20 Rest Break
15:20-16:00 Panel. Discussion 1: Promising Investment Directions for Radiopharmaceuticals Beyond 2026
Tao Xu(Moderator):Founder & CEO, SmartNuclide; Secretary-General, Tonacea Radiopharmaceutical Club
Li Li:Partner, StarsCapital
Chunguang Liu:Managing Partner, Tailong VC
Feng Yu:Founder & CEO, ELI Radiopharma
Xun Zhu:Honorary Director-General, Tonacea New Drug Talent Club
16:00-16:40 Panel. Discussion 2: The Synergy Between Isotopes and Radiopharmaceuticals
Jianguo Li (Moderator):Secretary and Deputy Director, Institute of Radiation Medicine, China Institute for Radiation Protection (CIRP)
Hong Liu:Head of the Scientific Research Project Management Department (Postdoctoral Workstation) of Guangzhou Pharmaceutical Holdings Limited, Board Director of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, Chairman and General Manager of Guangzhou Baiyunshan XIHE Health Pharmaceutical Co., Ltd
Jim Cai:Chairman & CEO, New RadiomedicineTechnology
Bo Shan:CEO, BoomRay Pharmaceuticals
Greg Chen:Founder & CEO, RadAlliance Therapeutics.
Xiang S Ye:CEO & CSO, AlphaGen Therapeutics
Heyun Chao:Senior Vice President, C Ray Therapeutics
16:40-17:30 Panel. Discussion 3:What Big Pharma Seeks in Radiopharmaceuticals?
Xiang Li (Moderator):Global Partner of Fosun; Senior Vice President, Fosun Pharma; Co-President & Chief Scientific Officer, Innovative Drug Division; CEO, Fosun New DrugsWuzhou Wan:President, Central Research Institute, Yunnan Baiyao Group
Fred Li:Director, Search & Evaluation, Novartis China
Duan Wang Dr.:Scientific Licensing Director, Collaborate to Cure China, Bayer Pharmaceuticals
Peng Yu:Clinical lead, Radiopharmaceutical R&D, AstraZeneca